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The ability of TLR agonists to promote adaptive immune responses is attributed to their
ability to robustly activate innate immunity. However, it has been observed that, for adju-
vants in actual use in research and vaccination, TLR signaling is dispensable for generating
humoral immunity. Here, we examined the role of TLR5 and MyD88 in promoting innate and
humoral immunity to flagellin using a prime/boost immunization regimen. We observed
that eliminating TLR5 greatly reduced flagellin-induced cytokine production, except for
IL-18, and ablated DC maturation but did not significantly impact flagellin’s ability to
promote humoral immunity. Elimination of MyD88, which will ablate signaling through TLR
and IL-1b/IL-18 generated by Nod-like receptors, reduced, but did not eliminate flagellin’s
promotion of humoral immunity. In contrast, loss of the innate immune receptor for profilin-
like protein (PLP), TLR11, greatly reduced the ability of PLP to elicit humoral immunity.
Together, these results indicate that, firstly, the degree of innate immune activation induced
by TLR agonists may be in great excess of that needed to promote humoral immunity and,
secondly, there is considerable redundancy in mechanisms that promote the humoral
immune response upon innate immune recognition of flagellin. Thus, it should be possible
to design innate immune activators that are highly effective vaccine adjuvants yet avoid the
adverse events associated with systemic TLR activation.
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Introduction
TLR-mediated recognition of structural components of microbial
pathogens plays a key role in the initiation of host defense.
Specifically, these germ-line-encoded PRR recognize and initiate
immune responses to a wide variety of microbial patterns,
including those of bacteria, viruses, parasites, nucleic acids,
carbohydrates, and lipids [1–4]. TLR agonists are classified into
three broad categories such as nucleic acids (TLR 3, 7, 8, 9),
lipids/lipopeptides (TLR 4, 1/2, 2/6), and protein (TLR 5, 11). Of
particular importance to this study, TLR5 recognizes the bacterial
protein flagellin [5], in its soluble/monomeric form, whereas
TLR11 recognizes profilin-like protein (PLP), made by Toxo-
plasma gondii [6]. Activation of most TLR, including TLR5 and
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TLR11, by their cognate ligands results in rapid nuclear
translocation of the transcription factor NF-kB and, consequently,
synthesis and secretion of a panel of pro-inflammatory cytokines.
Another class of PRR thought to play an important role in innate
immunity is the Nod-like receptors (NLR), which are expressed in
the cytosol. Of particular relevance to this study, two NLR
proteins, Ipaf and Naip5, have been reported to signal in response
to flagellin that attains an intracellular location [7–10]. In
contrast to TLR, the primary consequence of Ipaf signaling is not
to induce transcription or protein synthesis but rather to activate
caspase-1, which results in inflammasome-mediated processing/
secretion of pro-IL-1b and IL-18 to their mature bioactive forms
[11]. All TLR, except TLR3, signal, at least in part, via the myeloid
differentiation primary-response protein 88 (MyD88). Conse-
quently, MyD88-deficient mice have been a very useful tool in
investigating the roles of TLR signaling in numerous processes.
However, MyD88 is also required for signaling by the IL-1 and
IL-18 receptors. As these cytokines are important components of
NLR signaling, MyD88-deficient mice have deficiencies in both
NLR and TLR function.
PRR signaling is thought to play a key role both in the primary
immune clearance of pathogens and in promoting the develop-
ment of protective responses to prevent against future encounters
of similar pathogens [12]. Such an ability of TLR-mediated
signaling to promote adaptive immunity has led to the develop-
ment of approaches utilizing TLR agonists as vaccine adjuvants.
TLR agonists currently being developed for use as vaccine adju-
vants include monophosporyl lipid A, CpG oligodeoxynucleotide,
and single-stranded RNA/imidazoquinolins, which are ligands of
TLR4, TLR9, and TLR7/8, respectively [13–17]. Recently, there
has been particular interest in the TLR5 agonist, bacterial
flagellin, in part, because being a protein, it can be readily
formulated as a fusion-protein with a variety of antigens and,
furthermore, is amenable to being used as a DNA-based adjuvant.
Flagellin expression with bacterial or viral antigens leads to
innate immune functions, potent humoral immunity, and
protection against challenge with viruses including influenza A
and West Nile virus, bacterial infection such as Yersinia pestis
[18–23]. In addition to promoting adaptive immunity to other
antigens, flagellin is also a major target of adaptive immunity.
Specifically, upon infection with Salmonella species, flagellin is a
dominant antigen for CD41 and CD81 T-cell activation and
humoral immunity [24–27]. Flagellin is also a major target of
adaptive immunity in Crohn’s disease [28]. Purified flagellin has
been reported to induce Th1 and Th2 responses, and IgG and IgM
to itself and to other antigens indicative of the wide range of
adaptive immune responses it promotes [29–31]. While early
studies on flagellin’s elicitation of Ig indicated it was a thymus-
independent antigen, particularly when in a polymerized state
(i.e. flagella), recent studies performed in T-cell-deficient mice
indicate that generation of Ig to flagellin monomers or poly-
merized flagella are absolutely T-cell dependent [32].
A substantial amount of research has been devoted in recent
years to studying the means by which TLR signaling can promote
adaptive immunity. Such studies have led to the view that function
of adjuvants in general and TLR-based adjuvants in particular
results from their ability to induce cytokine production and DC
maturation. However, this notion has been challenged recently in
that Nemazee and co-workers reported that both a classical adju-
vant, namely complete Freund’s adjuvant, and an adjuvant that
includes a synthetic TLR4 agonist, namely Ribi/monophosporyl
lipid A, appeared to function efficiently in mice deficient in the two
major TLR signaling adaptor proteins MyD88 and TRIF (Toll/IL-1
receptor-domain-containing adapter-inducing interferon-b) [33].
The aim of this study is to examine the role of innate immu-
nity in the promotion of humoral immunity using purified
flagellin and mice lacking the molecules that mediate TLR- and/
or NLR-mediated recognition of this molecule. We demonstrate a
critical role for both TLR5 and MyD88 in mediating innate
immunity to flagellin, particularly acute systemic cytokine
production and DC activation, but, surprisingly, loss of TLR5 did
not have a substantial impact on the humoral response to purified
flagellin or co-administered OVA. MyD88-deficiency reduced, but
did not eliminate flagellin’s promotion of humoral immunity.
These results suggest that it may be possible to develop vaccine
adjuvants that effectively promote humoral immunity without
inducing robust activation of innate immunity.
Results
Generation of flagellin-specific antibodies in mice
lacking TLR5 or MyD88
A substantial body of research supports the notion that TLR are
important mediators of innate immunity and, consequently, key
initiators of adaptive immunity. However, as flagellin is one of only
two known well-defined protein TLR ligands, and minimal work
has been done with their receptor KO mice to date, little is known
regarding the nature of the adaptive immune response to a T-cell-
dependent protein TLR ligand. Given that, at least when measured
in a primary response, MyD88/ mice do not make antibody
responses to purified flagellin, and failed to make antibodies in
vaccine models in which flagellin serves as an adjuvant [34], we
expected that TLR5/ mice would lack antibody responsiveness to
flagellin. To test this notion, TLR5/ mice and WT littermates
were injected with 50mg of purified flagellin on days 0 and 28, and
serum isolated on days 0, 14, 28, and 42. Serum was assayed for
levels of flagellin-specific total IgG, IgG1, IgM, IgG2c, and IgG3. In
WT mice, flagellin elicited a strong IgG1 response whereas IgG2c
was only detected following the boost injection. Analysis of sera on
days 31 and 35 revealed the antibody response increased with
greater rapidity following the boost injection (data not shown),
suggesting the response following the second inoculation is that of
a classic memory-type response. Relative increases in IgM were
only moderate. Surprisingly, relative to WT mice, TLR5/ mice
exhibited only modest reductions of flagellin-specific Ig titers,
which achieved only statistical significance in the case of IgG1
(Fig. 1). Flagellin-specific IgG3 was undetectable in all mouse
groups (data not shown).
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In light of previous reports from our laboratory and others
that demonstrated a requirement for MyD88 in flagellin-induced
antibody responses [32, 34], we next examined the role of
MyD88 in the prime/boost immunization regimen. In accordance
with previous findings, flagellin-specific Ig was markedly
reduced in MyD88/ relative to similarly treated WT mice with
most MyD88 failing to exhibit a detectable titer in response to
primary injection (Fig. 2). Total IgG and IgG1 were readily
detectable following flagellin in MyD88/ mice given a second
injection of flagellin, yet, unlike TLR5/ mice, flagellin-specific
IgG and IgG1 titers of MyD88/ mice were markedly less
than those of WT mice. In further contrast to TLR5/, MyD88
were unable to produce significant levels of anti-flagellin
IgG2c. In addition, while flagellin-specific IgM was elevated
by day 7 following boost, their titers dropped by day 14
whereas those of WT mice remained elevated. These results
suggest that there exists a MyD88-dependent, TLR5-independent
means by which flagellin promotes the humoral immune
response to itself. However, these results indicate that neither
TLR5 nor MyD88 are absolutely critical for an adaptive immune
response to flagellin.
Flagellin’s elicitation of Ig in TLR5-deficient mice not
due to activation of other TLR
One potential explanation of why flagellin elicited antibodies
efficiently in mice lacking TLR5 was that, despite it being HPLC-
purified and undergoing rigorous in vitro and in vivo purity
tests [30, 35], our flagellin contained a contaminant that
was activating another TLR. We first considered the possibility
that our flagellin contained LPS, which is known to
contaminate many purified proteins. Although our previous
demonstration that flagellin’s ability to elicit antibodies was not
diminished in C3H/HeJ mice, which lack functional TLR4,
suggest LPS-induced signaling was not involved in this process
[32], it seemed possible that our flagellin may still contain a
minute amount of LPS that serves as a ‘‘back-up’’ innate immune
activator in TLR5/ mice. To address this possibility, we
generated TLR5//TLR4/ mice and evaluated their ability
to generate antibodies in response to the prime/boost inoculation
regimen described above. We observed that TLR5//TLR4/
mice generated antibodies to flagellin as robustly as identically
treated WT mice (Fig. 3). Thus, TLR4-mediated LPS-induced
signaling has no role in the ability of our flagellin preparation to
elicit antibodies. Furthermore, these results rule out the
possibility that flagellin itself is recognized by TLR4 – a possibility
suggested by the report that TLR5/TLR4 heteromeric complexes
mediated flagellin-induced induce nitric oxide production by
macrophages [36].
We next generated mice lacking both TLR2 and TLR5 to
address the possibilities that either flagellin can signal through
TLR2 and/or that our flagellin preparation might contain TLR2
agonists such as lipopeptide, which is present in all gram-nega-
tive bacteria. Furthermore, as TLR2 can dimerize with TLR1 and
TLR6, and is necessary for their function, studying responses of
Figure 1. Induction of flagellin-specific humoral immunity in TLR5-deficient mice. Mice lacking TLR5 and WT littermates were immunized with
50 mg of flagellin on days 0 and 28. Flagellin-specific Ig was assayed on indicated days by ELISA. Each point represents the serum antibody titer to
flagellin for an individual mouse. Gray circles, WT controls (WT); open triangles TLR5/ (KO). Asterisk indicates statistically significant difference
between WT and KO (po0.05).
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TLR5//TLR2/ mice also addresses the possibility that our
flagellin might have ligands for these TLR. Analogous to the case
for TLR4, flagellin elicited self-specific antibodies equally well in
WT mice versus mice lacking both TLR5 and TLR2 (Fig. 3B).
Lastly, because TLR11, the receptor for the T. gondii protein
‘‘PLP’’ [6] is the TLR most related to TLR5 and has been suggested
as a possible flagellin receptor [37], we examined the role of this
TLR in generation of flagellin-specific Ig. We observed that, in
response to flagellin treatment, TLR11/ mice generated anti-
bodies to a similar extent as WT mice (data not shown) arguing
against this possibility.
Flagellin’s adjuvanticity is maintained in the absence
of TLR5
Next, we examined the role of TLR in flagellin’s adjuvant
function. Mice were injected with 50 mg of OVA alone, or OVA
mixed with 50 mg of flagellin, on days 0 and 28. This regimen is
similar to that which Didierlaurent et al. observed results in a
strong MyD88-dependent IgG1 response to OVA following the
second injection of OVA/flagellin [34]. In accordance with this
study, we observed that MyD88/ mice given OVA/flagellin
exhibited anti-OVA antibody titers that were significantly less
Figure 2. Induction of flagellin-specific humoral immunity in MyD88-deficient mice. Mice lacking MyD88 and WT control mice were immunized
with 50mg of flagellin on days 0 and 28. Flagellin-specific Ig was assayed on indicated days by ELISA. Each point represents the serum antibody titer
to flagellin for an individual mouse. Gray circles, WT controls (WT); open triangles MyD88/ (KO). Asterisk indicates statistically significant
difference between WT and KO (po0.05).
Figure 3. Induction of flagellin-specific humoral immunity in, mice lacking TLR 4 and 5, or 2 and 5. Mice lacking the indicated TLR and WT
littermates were immunized with 50 mg of flagellin on days 0 and 28. Flagellin-specific Ig was assayed on indicated days by ELISA. Each point
represents the serum antibody titer to flagellin for an individual mouse. (A) Gray circles, WT littermates (WT); open triangles TLR4/,TLR5/
(DKO). (B) Gray circles, WT littermates (WT); open triangles TLR2/,TLR5/ (DKO).
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than similarly treated WT mice (Fig. 4). However, anti-OVA titers
in MyD88/ mice given OVA/flagellin were still substantially
higher than MyD88/ mice given OVA alone. Thus, absence of
MyD88 significantly reduced but did not eliminate flagellin’s
ability to promote humoral immunity. In contrast to MyD88/
mice, flagellin promoted antibodies to OVA as efficiently in
TLR5/ mice as in WT littermates, indicating that TLR5 is not
required for flagellin to promote the humoral immune response
to a by-stander antigen. We repeated this experiment using only
10 mg of flagellin. This smaller dose of flagellin also robustly
promoted generation of anti-OVA antibodies in both WT and
TLR5/ mice (antibody titers to mice given OVA only and OVA/
flagellin were, respectively, WT: 513738 and 26 65473842
versus TLR5/: 5467146 and 34 67678632, not significant).
Flagellin also efficiently promoted antibody responses to OVA in
mice lacking both TLR5 and TLR4, arguing against the notion
that a contaminating TLR4 ligand plays an important role in the
responses we observed in TLR5-deficient mice.
We further addressed the possibility of contaminants via
biochemical approaches. First, our preparation of flagellin was
exposed to trypsin immobilized on agarose beads. Such a treat-
ment will cleave proteins such as flagellin into peptides that lack
the ability to activate TLR5, but does not alter the bioactivity of
numerous other TLR agonists (e.g. LPS, CpG DNA, peptidogly-
can). The ability of such a trypsin-treated flagellin to serve as an
adjuvant was assessed by measuring anti-OVA antibodies in mice
injected with OVA alone or OVA1trypsin-treated flagellin. We
observed that trypsin treatment eliminated all of flagellin’s ability
to promote antibodies to OVA (mice getting OVA only or OVA/
trypsinsized flagellin had anti-OVA titers below 100 – limit of
detection). Thus, our preparation of flagellin does not contain
any non-proteinaceous materials with adjuvant function. Lastly,
we examined whether a mock preparation of flagellin had any
adjuvant function. Specifically, we performed all the steps we
utilize to generate purified flagellin but did so using supernatant
from the isogenic flagellin-deficient Salmonella mutant Sl3201
(fliC/fljB), and isolated the same HPLC fractions that would
have contained flagellin if WT Salmonella had been utilized. Mice
were inoculated with OVA or OVA1mock flagellin (amount
equivalent to above experiments using actual flagellin) and OVA-
specific antibodies measured. Such a mock flagellin had no ability
to promote antibodies to OVA (data not shown), further indi-
cating that the adjuvant activity observed herein is indeed that of
flagellin rather than a contaminant.
Flagellin-induced cytokine production is mainly TLR5
dependent
To understand how flagellin might maintain full adjuvant
function in the absence of TLR5 and partial adjuvant function
in the absence of MyD88, we examined early events in the innate
immune response that are thought to shape adaptive immunity.
In general, TLR signaling is thought to promote adaptive
immunity by mediating secretion of cytokines and cell-surface
expression of co-stimulatory molecules on APC [38]. Thus, we
examined how loss of TLR5 and MyD88 affected these events in
response to flagellin. First, we examined the role TLR5 plays in
systemic innate immune responses to purified flagellin. Though
previous studies have reported flagellin-induced cytokine produc-
tion is dependent on TLR5 and MyD88 in vivo [5, 39–43], we
broadly investigated if the absence of either of these two
molecules leads to a complete loss of cytokines, a delay in
cytokine production, or merely a weakened response over a 24-h
period. Flagellin-injected TLR5/, MyD88/, and WT control
mice were bled at 0, 1, 2, 4, 8, or 24 h and their sera were
analyzed using a multiplex cytokine assay. Loss of TLR5 resulted
in a complete absence of IL-12 (p40), TNF-a, IL-17, RANTES,
MIP1b, and Eotaxin, cytokines normally produced in WT mice
(Fig. 5). Flagellin did induce statistically significant levels of IL-6,
MCP-1, and G-CSF in TLR5/ mice with kinetics similar to those
seen in WT littermates, although at greatly reduced levels relative
to these WT mice. In contrast, loss of TLR5 only moderately
reduced serum elevations in IL-1a and had no significant impact
upon induction of IL-18. Mice lacking MyD88 exhibited a
complete loss of elevation in all measured serum cytokines in
response to flagellin except IL-18, which was significantly
induced albeit at a moderately reduced level relative to WT
mice. Flagellin did not induce detectable elevations in serum
IL-1b, in WT nor KO mice, consistent with our previous finding
that flagellin’s elicitation of specific antibodies proceeds normally
in IL-1R-deficient mice [44].
Cytosolic flagellin receptors are not required for
humoral immune responses to flagellin
Recent findings demonstrate that Ipaf and Birc1e/Naip5,
members of the cytosolic nucleotide-binding oligomerization
domain – leucine-rich repeat family of proteins, are required
for cytosolic flagellin to activate caspase-1 and induce IL-1b
secretion in macrophages infected by Salmonella or Legionella
[7, 8, 45]. That flagellin-induced IL-18 production in both
Figure 4. OVA-specific humoral immunity in TLR-deficient mice
inoculated with OVA and flagellin. Mice (WT and indicated TLR-
deficient mice) were immunized with OVA alone or co-injected with
50 mg of OVA and 50mg of flagellin on days 0 and 28. OVA-specific IgG1
was assayed on day 42 by ELISA. Each point represents the serum IgG1
titer to OVA for an individual mouse. Circles, WT controls (WT);
triangles, TLR-deficient mice. A ‘‘1’’ sign indicates mice were given
flagellin in addition to OVA.
Eur. J. Immunol. 2009. 39: 359–371 HIGHLIGHTS 363
& 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
TLR5/ and MyD88/ mice is in accordance with these
findings although this pathway is not thought to be capable of
recognizing ‘‘free’’, or extracellular, flagellin [7, 8]. Moreover,
this observation suggested that IL-18 might drive adaptive
immunity in these TLR-deficient mice. To assess the role IL-18
may play in flagellin’s promotion of adaptive immunity, IL-18/
mice were injected with flagellin and flagellin-specific Ig
measured 14 days later. No significant difference in flagellin-
specific IgG titer was noted in IL-18/ mice compared with WT
controls, indicating that IL-18 is not required to promote
flagellin-specific humoral immunity (data not shown).
We next examined the contribution of Ipaf to flagellin-
induced immune responses in vivo. Although our approach
utilized purified flagellin and thus lacks the active cytosolic entry
provided by the Salmonella Pathogenicity Island 1 Type III
secretion system, it was conceivable that flagellin may enter a
cell’s cytosol via an unknown mechanism and induce an immune
response [46]. Thus, we examined how loss of Ipaf impacted
flagellin-induced cytokine production and elicitation of anti-
bodies. Keratinocyte-derived chemoattractant (KC) was
measured to serve as a general indicator of a TLR5-mediated
cytokine whereas IL-18 was measured as a potential indicator of
activation of NLR-mediated detection of flagellin. We observed
that Ipaf/ mice exhibited WT levels of acute serum KC and
flagellin-specific IgG, suggesting that this TLR5-independent
pathway is not required for these flagellin-induced immune
responses, at least in TLR5-competent mice (Fig. 6A). Our efforts
to discern whether the flagellin-induced IL-18 production exhib-
ited by TLR5/ and MyD88/ mice was mediated by Ipaf did
not prove informative in that we were unable to detect any
increase in serum IL-18 in both Ipaf/ and their WT littermate
control mice (data not shown), possibly due to a difference in
mouse background strain or housing conditions of these mice.
Interestingly, Ipaf/ mice did exhibit lower basal levels of serum
IL-18 in comparison with their WT littermate controls, suggesting
some degree of Ipaf-dependence for IL-18 production.
Naip5 (Birc1e), another NLR, has been found to restrict
intracellular replication of Legionella pneumophila in mouse
macrophages [47]. An inability to detect intracellular flagellin in
macrophages and mice containing a non-functional Naip5 allele
(A/J mice) confers susceptibility to Legionella infection [10, 48].
We thus investigated whether the intracellular flagellin-signaling
Figure 5. Serum cytokine levels in TLR5/ and MyD88/ given flagellin. TLR5/, TLR51/1, and MyD88/ mice were bled before any treatment
(0 h), then immunized i.p. once with 50mg of flagellin and bled 1, 2, 4, 8, or 24 h later. Closed circles, TLR51/1 mice; open circles, TLR5/ mice,
closed triangles, MyD88/ mice. Note MyD88/ mice sera were analyzed only for IL-6, KC, G-CSF, MCP-1, IL-1a, and IL-18. Data are means7SEM;
n 5 4–5 mice.
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molecule Naip5 may have an effect on immune responses to
flagellin. Although there is not an isogenic control strain carrying
functional Naip5, to which we could directly compare A/J mice,
we observed that, relative to WT mice on the C57BL/6 and Balb/c
backgrounds, A/J mice exhibited robust levels of acute serum KC
acute and flagellin-specific IgG, suggesting that this cytosolic
flagellin detector also does not impact humoral immunity to
flagellin (Fig. 6B). Interestingly, A/J mice also exhibited eleva-
tions in serum IL-18 in response to flagellin. This result is in
accordance with recent general findings that some aspects of Ipaf
function, in particular, caspase-1 activation, are independent of
Naip5 [49, 50].
TLR5 and MyD88 are needed for in vivo APC activation
DC activation is considered a critical step in the initiation of
adaptive immunity [51] and, indeed, flagellin can induce strong
up-regulation of co-stimulatory molecules on DC when adminis-
tered in vivo [34, 37]. Such a DC activation is commonly
measured in vivo by administering a potential stimulus, isolating
splenocytes, and measuring surface expression levels of CD80,
CD86, or CD40 on CD11chi cells by flow cytometry. Thus, to
understand how flagellin promotes adaptive immunity, we
utilized this approach to examine how loss of TLR5 or MyD88
impacted upon the ability of flagellin to induce DC activation. In
agreement with previous reports, these splenic DC from
TLR5/ and MyD88/ mice did not up-regulate/activation 6 h
after primary or secondary flagellin treatment (Fig. 7
and data not shown) [34, 40]. To address the possibility that DC
activation might be merely delayed, we performed similar
analysis 24 h following flagellin treatment but again
observed that CD11chi cells from TLR5/ mice failed to up-
regulate these cell-surface markers in response to flagellin
(data not shown). Potent LPS-induced CD40, CD80 (B7.1),
and CD86 (B7.2) up-regulation demonstrated that our
TLR5/ mice retained the ability to respond normally to
another TLR ligand (data not shown). Thus, flagellin’s
promotion of humoral immunity in TLR5/ and
MyD88/ mice occurred without detectable activation of
splenic DC.
It has been reported that direct activation of MyD88 in B cells
is required to elicit robust humoral immunity in response
to TLR agonists and that B cells express TLR5, at least at the
mRNA level [52]. Thus, we sought to determine if purified
flagellin directly activates resting B cells ex vivo. Purified splenic B
cells were incubated with flagellin (100 ng/mL–10 mg/mL) or a
positive-control stimulus, LPS, which is known to activate
these cells. B-cell activation was assessed by measuring
surface expression of CD69. Neither low nor high concentrations
of flagellin up-regulated CD69 expression, while various doses
of LPS were able to induce impressive up-regulation of this
molecule (Fig. 8). These results suggest that flagellin does not
induce direct activation of B –cells, and thus direct activation of B
cells by flagellin is unlikely to play a role in flagellin’s promotion
of humoral immunity.
TLR11/ mice do not generate PLP-specific antibodies
PLP is an immunodominant antigen of T. gondii, which has
been shown to be recognized by TLR11 [6, 53]. As PLP and
TLR11 is the only other established protein ligand–TLR
cognate pair, we investigated whether the relative
Figure 6. Innate and humoral immune responses to flagellin in Ipaf/ and A/J mice. Mice were immunized once with 50mg flagellin/100 mL PBS/
mouse. (A) Ipaf/ and WT control mice. Serum KC levels at 4 h; flagellin-specific IgG titers on days 0 and 14. (B) A/J (non-functional Naip5 allele)
mice. Serum KC and IL-18 levels at 2 h; flagellin-specific IgG titers on days 0 and 14. Data are means7SEM; n 5 5–6 mice.
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unimportance of a TLR for generating specific antibodies to its
purified protein ligand was a general phenomenon or was specific
for flagellin/TLR5. Mice lacking TLR11 and WT control
mice were administered a prime/boost regimen of PLP analogous
to that utilized for flagellin. We observed that, in contrast to
the TLR5/flagellin interaction, generation of PLP-specific
antibodies was greatly diminished in TLR11/ mice when
assayed in response to both primary injection and 14
days after boosting (Fig. 9). Thus, PLP appears to elicit
humoral immunity via activation of a single non-redundant
pathway of innate immunity. In contrast, flagellin may utilize
multiple pathways of activating innate immunity so that even
markedly reducing its ability to activate innate immunity will not
severely attenuate its ability to promote humoral immune
responses.
Discussion
Nearly two decades ago, C. A. Janeway, Jr. proposed a two-signal
model for activation of adaptive immunity to non-self antigens.
‘‘Signal one’’ was defined as the interaction between a specific
ligand and its antigen receptor, whereas ‘‘signal two’’ constituted
host-cell activation via a microbially induced, antigen recogni-
tion-independent event [54]. This model provided a potential
explanation for the well-established ability of bacterial products
to promote adaptive immune responses. The discovery of TLR
and the deciphering of how they signal in response to various
ligands provided this model a molecular mechanism by which
innate immunity controls adaptive immunity, namely by activat-
ing signaling events that induced expression of immunostimula-
tory/pro-inflammatory cytokines and surface co-stimulatory
Figure 7. Effect of loss of TLR5 and MyD88 on flagellin-induced
activation of splenic DC. WT, TLR5/, and MyD88/ mice were
injected once i.p. with 50 mg of flagellin/100 mL of PBS/mouse or 100 mL
PBS/mouse. After 6 h, splenocytes were collected, stained, and
analyzed by flow cytometry. Histograms show expression levels of
CD80, CD86, and CD40 on CD11chigh gated live cells. Filled gray area,
PBS-treated mice; heavy line, flagellin-treated mice. These data are
from an individual experiment utilizing spleens pooled from three
mice per condition. The results are representative of three separate
experiments that showed an identical pattern of results.
Figure 8. Effect of flagellin on CD69 expression of splenic B cells ex
vivo. Purified resting splenic B cells were stimulated in culture at 1 106
cells/well with media or indicated concentrations of LPS or flagellin.
After 24 h, cells were collected and analyzed by flow cytometry.
Histograms show expression levels of CD69 on CD191live cells. The
results are from a single experiments and representative of three
parallel experiments that showed an identical patterns of results.
Figure 9. Induction of PLP-specific humoral immunity in TLR11-
deficient mice. Mice lacking TLR11 and WT littermates were immu-
nized with 10mg of T. gondii PLP on days 0 and 28. PLP-specific Ig was
assayed on indicated days by ELISA. Each point represents the serum
antibody titer to PLP for an individual mouse. Gray circles, WT controls
(WT); open triangles TLR11/ (KO). Asterisk indicates statistically
significant difference between WT and KO (po0.05).
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molecules on APC [55–57]. This model held that flagellin’s ability
to promote adaptive immunity to itself and by-stander antigens
was underlaid by its ability to activate TLR5 rather than the long-
held notion that flagellin was highly immunogenic due to its
ability to polymerize and thus cross-link antigen receptors [30,
32]. However, herein we observed that loss of TLR5 did not have
a substantial impact upon the ability of flagellin to promote the T-
cell-dependent antibody response to itself or a by-stander
antigen. This observation parallels the recent report by Nemazee
and co-workers that both a classic adjuvant based on mycobac-
terial extract and one based on a synthetic TLR4 agonist
functioned independently of all known TLR-signaling pathways
[33]. Thus, at least in the case of humoral immunity, which is the
basis for protection of most currently used vaccines, TLR
signaling may not be as important as previously suggested.
However, our conclusions go beyond simply supporting some
aspects of their work. Rather, by measuring the extent to which
loss of TLR5 and MyD88 impacted upon various aspects of the
flagellin-induced innate response, our study allows for mechan-
istic assessment of how flagellin may be promoting adaptive
immunity in the absence of TLR5.
The ability of flagellin to function as an adjuvant in TLR5-
deficient mice occurred despite a substantial, but not complete,
loss of cytokine induction and without detectable maturation of
splenic DC. We utilized a variety of approaches to investigate
whether flagellin’s bioactivity in TLR5-deficient mice was the
result of a potential contaminant in our flagellin preparation but
did not find evidence to support this possibility. Interestingly,
mice lacking TLR5 and TLR4, which was our prime suspect to
recognize any potential contaminant, appeared to respond
slightly better to flagellin than mice lacking only TLR5. The
reason for this difference may result from TLR5-deficient mice
having basal alterations in gene expression that can be envisaged
to influence subsequent immune responses to exogenous ligands
[58]. Such basal alterations are not present in mice lacking both
TLR4 and TLR5, thus potentially accounting for modestly greater
antibody responses elicited by flagellin in TLR5//TLR4/
mice. Although the experiments we have performed herein may
not allow us to be certain that our flagellin does not contain some
substance other than flagellin that can promote immune
responses, regardless, we can conclude that the level of cytokine
production and DC maturation induced by flagellin in WT mice is
clearly in great excess of what is required to promote a humoral
immune response. Yet, although differences in antibody respon-
ses between WT and TLR5/ mice differed only modestly, that
responses were modestly higher and more uniform in WT mice
suggests that the robust cytokine/DC response of WT mice may
increase the likelihood that individual mice will make a robust
antibody response. This notion is consistent with clinical studies
in which synthetic analogs of CpG DNA added to a hepatitis B
vaccine markedly increased the rate of sero-conversion following
primary inoculation while only moderately increasing titers
following multiple inoculations [59].
Flagellin also functioned as an adjuvant in mice lacking
MyD88, although to a significantly lesser extent than in WT mice.
A potential explanation for this difference is that MyD88/ mice
are not only deficient in signaling by TLR5 but, because MyD88 is
required for signaling in response to both IL-1b and IL-18, are
effectively deficient in being able to ultimately respond to signals
initiated via NLR such as Ipaf, which function in large part by
generating mature IL-1b and IL-18 via post-translational proces-
sing [7]. Thus, in the absence of TLR5 signaling, perhaps flagel-
lin’s adjuvanticity is mediated by NLR-generated IL-18.
Intriguingly, recent reports indicate that NLR-mediated IL-18
generation is the central mechanism by which aluminum-based
adjuvants function [60, 61]. Should the ability of flagellin to
promote humoral immunity in TLR-deficient mice rely
on IL-18 via a mechanism analogous to that used by Alum, it may
explain why flagellin’s adjuvant function is reduced, but not
entirely eliminated, in MyD88-null mice in that a portion of
Alum’s adjuvant function is MyD88 independent but IL-18
dependent [62].
Although the extent of the innate immune response induced
by flagellin may be far in excess of what is needed to promote a
humoral immune response, the above-described difference
between TLR5 and MyD88 suggest that residual innate response
observed in flagellin-treated TLR5/ mice may indeed be
limiting to this aspect of the adaptive immune response. This
notion would predict that simultaneous elimination of TLR5,
Ipaf, Naip5, and perhaps other yet-to-be defined flagellin recep-
tors would completely ablate flagellin’s ability to function as an
adjuvant. By this reasoning, it seems reasonable to speculate that
the profoundly reduced ability of TLR11-null mice to generate
antibodies to PLP reflects that mice lack additional significant
means of innately recognizing this molecule. Such a lack of
redundancy could reflect that PLP is unique to select parasites
while flagellin, in mediating motility, plays a central role in the
function of many bacteria. Indeed, the evolutionary loss of
functional TLR11 from humans argues that immune recognition
of PLP may not be especially important.
Thus, in conclusion, neither do we question Dr. Janeway’s
proposal that innate immune recognition of conserved microbial
patterns by germ-line-encoded receptors is necessary for adaptive
immune responses to microbes nor do we question the notion
that TLR are the front line class of such receptors. Rather, we
propose a model with redundancy in which molecules with
critical microbial function can be recognized by a series of germ-
line-encoded receptors. Some of these receptors may be viewed
as ‘‘alternate recognition molecules’’ in that they promote low-
level signals that may be hard to detect in vivo, yet such signals
are immunologically highly significant in that they can promote
adaptive immunity particularly in the case of recall responses.
The robust signals generated by a product’s ‘‘primary’’ innate
immune receptor may be more important for acute responses to
microbes but may also assure rapid generation of primary
adaptive responses, which could be important in clearance of a
primary infection. These findings have important implications for
vaccine design in that they show robust adaptive immune
responses are achievable without potent TLR-mediated innate
immune responses, which are often associated with adverse
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events. Consequently, perhaps targeting of non-TLR immune
sensors may ultimately provide the safest means of generating




TLR5/ and MyD88/ mice were generated as previously
described [63, 64]. TLR5/ mice used here were backcrossed
eight times onto a C57BL/6J background, and WT littermates were
used as controls. MyD88/ mice on a C57BL/6J background were
a gift from Melanie Sherman (Emory University, Atlanta, GA). These
mice were bred at Emory University. C57BL/6J, B6.129-Tlr2tm1Kir/
J (Tlr2/), B6.129P2-Il18tm1Aki/J (Il18/), and A/J (non-
functional Naip5) were obtained from The Jackson Laboratory
(Bar Harbor, ME). Except for A/J mice, these mice are all on the
C57BL/6 background. TLR11/ mice are on a mixed background.
These mice were generated by S. Ghosh (Yale University, New
Haven, CT) [65] and provided to us by Doug Golenbock (UMass
Med. ctr. Worcester, MA). Ipaf/mice were generated as described
previously [7]. TLR5/TLR4/ mice and controls were generated
by first crossing TLR5/ N7 males and C57BL/10ScNJ (Tlr4 gene
deletion) females (The Jackson Laboratory), then crossing the
heterozygous F1 generation. Confirmation of double-deficient and
WT littermates was done by genotyping the F2 generation for Tlr5
and for Tlr4. TLR5/TLR2/ mice and WT controls were
generated by first crossing TLR5/ N7 females with TLR2/
males (Jackson Laboratory), then crossing the heterozygous F1
generation. Genotyping of the F2 generation for Tlr5 and Tlr2
identified double-deficient mice and WT littermates. All mice with
the exception of Ipaf/ and Ipaf1/1 were housed at Emory
University. Animal studies were approved by the Institutional
Animal Care and Use Committee of Emory University.
Injections
Native flagellin was isolated from Salmonella typhimurium and its
purity verified as previously described [30, 35]. Flagellin injections
were given i.p. at 50mg/100mL PBS/mouse. OVA (grade IV; Sigma,
St. Louis, MO) was given i.p. at 50mg/100mL PBS/mouse. LPS
from S. typhimurium (Sigma) was given at 25mg/100mL PBS/
mouse. PLP was isolated from T. gondii as described previously [6].
PLP was administered i.p. at 10mg/100mL PBS/mouse. Mouse
serum was isolated from blood obtained from puncture of the
submandibular pouch. Sera were stored at20 or801C until use.
DC isolation and flow cytometry
Splenic CD11chi cells, herein referred to as splenic DC, were isolated
from three pooled spleens of mice injected i.p. 6 or 24 h previously
with 50mg of flagellin/100mL of PBS/mouse, 25mg of LPS/100mL
of PBS/mouse, or 100mL of PBS/mouse. Spleens were digested
with 1 mg/mL of collagenase type IV (Worthington Biochemical,
Lakewood, NJ) in complete DMEM12% FBS for 30 min at 371C.
Single-cell suspensions were treated with ammonium chloride to
lyse red blood cells, washed twice in PBS supplemented with 2 mM
EDTA and 1% FBS and mesh filtered before staining for flow
cytometry. Flow cytometric stains were performed for 30 min at 41C
in 2.4G2 hybridoma culture supernatant (anti-I-Ak/FcãRIII/II) to
block non-specific binding. Splenocytes were stained with anti-
mouse APC-CD11c, FITC-CD80 (B7-1), FITC-CD86 (B7-2), and
FITC-CD40 (eBioscience). Data were collected on a FACSCalibur
cytometer (Becton Dickinson, Franklin Lakes, NJ) and analyzed
using CellQuest software (BD Biosciences, San Jose, CA).
Cytokine analysis
TLR5/ and MyD88/mouse sera were evaluated for cytokines
using a custom multiplex cytokine assay kit according to the
manufacturer’s specifications (Bio-Rad, Hercules, CA). Analysis
was performed on a Luminex 100 machine running Bioplex
Manager version 4.0 (Bio-Rad). Additional cytokine analyses
were obtained using mouse IL-6, mouse KC, and mouse TNF-a
cytokine ELISA kits (R&D Systems, Minneapolis, MN).
Antibody analysis
Antibody ELISA plates (MP Biomedicals, Solon, OH) were coated
with 2mg of OVA or 100 ng of S. typhimurium FliC/well in 0.1 M
NaHCO3 buffer (pH 9.6) overnight at 41C. Plates were washed in
ELISA wash buffer (HBSS, 0.5% goat serum, 0.1% Tween-20)
and serum applied in various dilutions for 1 h at 371C. After three
additional washes, HRP-conjugated sheep anti-mouse IgG (GE
Healthcare, Piscataway, NJ), HRP-conjugated goat anti-mouse
IgG1 (Caltag Laboratories, Burlingame, CA), HRP-conjugated
goat anti-mouse IgG2c (Southern Biotech, Birmingham, AL), or
donkey biotinylated-anti-mouse IgM (Jackson Immunoresearch,
West Grove, PA) were added 1:1000, 1:2000, 1:2000, and
1:1000, respectively, in wash buffer for 1 h at 371C. Anti-IgM
plates were further incubated for 30 min with 100 mg/mL of
streptavidin–HRP (Jackson Immunoresearch) at 371C. Plates
were developed using tetramethylbenzidine substrate (Kierke-
gaard and Perry Laboratories – KPL, Gaithersburg, MD), stopped
using H2SO4, and read at 450 nm on a SpectraMax Plus plate
reader (Molecular Devices, Sunnyvale, CA). Antibody titers were
defined by the reciprocal of the serum dilution equivalent to three
times ELISA plate background (coated, no sample).
Statistical analysis
Significance was determined using both Student’s t-test and
Mann–Whitney test (GraphPad Prism software, San Diego, CA),
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which agreed in every instance. Differences were noted as
significant when po0.05.
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